Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma - Proceedings from a Clinical Investigator Think Tank

In these audio proceedings from a closed Think Tank meeting held in July 2013, the invited faculty discuss and debate the current nonprotocol management of Hodgkin and non-Hodgkin lymphoma as well as promising research strategies in these areas. The roundtable discussion focused on key presentations and papers and actual cases managed in the practices of the faculty where these data sets factored into their decision-making. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.

Listen to audio excerpts

Track 1: Case discussion: A 65-year-old patient with chronic lymphocytic leukemia (CLL) with a 17p deletion experiences relapse through multiple lines of therapy before achieving a near complete response to the BTK inhibitor AVL-292 on
a clinical trial
Track 2: Therapeutic options for patients with relapsed/refractory CLL with deletion 17p
Track 3: Activity of the PI3K delta inhibitor idelalisib (GS-1101) and the BTK inhibitor ibrutinib in relapsed/refractory CLL
Track 4: Tolerability of idelalisib and ibrutinib in relapsed/refractory CLL
Track 5: Overview and design of the Phase III CLL11 trial of obinutuzumab (GA101) with chlorambucil or rituximab with chlorambucil versus chlorambucil alone in previously untreated CLL
Track 6: Differences in the mechanisms of action of the anti-CD20 antibodies rituximab, ofatumumab and obinutuzumab
Track 7: Stage I results from the CLL11 trial
Track 8: Pharmacokinetics of obinutuzumab versus rituximab in CLL
Track 9: Results from the Phase III SWOG-S0016 trial of R-CHOP versus CHOP > 131I-tositumomab for previously untreated follicular lymphoma (FL)
Track 10: Activity of ibritumomab tiuxetan as up-front therapy for patients with FL
Track 11: Use of radioimmunotherapy (RIT) in clinical practice
Track 12: ECOG-E2408: A Phase II trial of bendamustine in combination
with rituximab (BR) > rituximab versus BR in combination with bortezomib > rituximab versus BR > lenalidomide/rituximab (R2) in high-risk FL
Track 13: Activity of bortezomib, alone and in combination with rituximab, in patients with FL
Track 14: Pharmacokinetics of the investigational oral proteasome inhibitor ixazomib (MLN9708)
Track 15: Case discussion: A 48-year-old patient previously treated for Stage IV FL who presents with disease progression and is treated with RIT remains in complete remission 2 years later
Track 16: Treatment options for patients with minimally symptomatic relapsed/refractory FL
Track 17: Role of transplant in FL in the rituximab era
Track 18: Consideration of transplant after RIT
Track 19: Case discussion: A 70-year-old patient treated with multiple lines of therapy for advanced-stage mantle-cell lymphoma (MCL)
Track 20: Therapeutic options for patients with MCL who experience disease progression following autologous stem cell transplant (ASCT)
Track 21: Sequencing of lenalidomide and bortezomib in relapsed/refractory MCL
Track 22: Activity of the antibody-drug conjugate brentuximab vedotin in Hodgkin lymphoma (HL)
Track 23: Critical evaluation of an ongoing Phase III trial of ABVD versus AVD in combination with brentuximab vedotin as front-line therapy for advanced classical HL
Track 24: Case discussion: A 34-year-old patient with relapsed/refractory advanced-stage HL experiences a complete response with brentuximab vedotin
Track 25: Clinical experiences with brentuximab vedotin-associated neurotoxicity
Track 26: Results of a retrospective study of brentuximab vedotin prior to reduced-intensity allogeneic stem cell transplant for relapsed/refractory HL
Track 27: Optimal duration of brentuximab vedotin therapy
Track 28: Potential use of brentuximab vedotin as up-front therapy or as a bridge to ASCT
Track 29: Results of a Phase II trial of PET-adapted sequential therapy with brentuximab vedotin and augmented ICE in relapsed/refractory HL
Track 30: Case discussion: An 87-year-old patient with newly diagnosed advanced-stage HL with significant comorbidities
Track 31: Case discussion: A 76-year-old patient previously treated for Stage IIIA, CD30-negative peripheral T-cell lymphoma (PTCL) experiences a partial response to pralatrexate
Track 32: Limitations in the measurement of CD30 status and potential benefit with brentuximab vedotin in “CD30-negative” non-Hodgkin B- and T-cell lymphomas and HL
Track 33: Clinical experiences with and tolerability of pralatrexate and romidepsin in PTCL
Track 34: Up-front treatment for patients with advanced PTCL
Track 35: Case discussion: A 61-year-old patient with Stage IV, ALK-negative anaplastic large-cell lymphoma
Track 36: Ongoing trials evaluating brentuximab vedotin-based therapies in CD30-positive T-cell lymphoma
Track 37: Results from a Phase II trial of the novel Aurora A kinase inhibitor alisertib (MLN8237) in patients with aggressive B- and T-cell non-Hodgkin lymphoma
Track 38: BELIEF: Results of a Phase II trial evaluating the novel pan-histone deacetylase inhibitor belinostat in relapsed/refractory PTCL
Track 39: Perspective on reported responses to brentuximab vedotin in patients with clinically CD30-negative HL
Track 40: Initial results of ongoing trials evaluating R-CHOP in combination with lenalidomide (R2-CHOP) as initial therapy for aggressive B-cell lymphomas
Track 41: Differential responses to lenalidomide in the germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma (DLBCL)
Track 42: Case discussion: An 88-year-old patient with severe facial pain and multiple comorbidities is diagnosed with Stage IV-E DLBCL
Track 43: Perspectives on the use of CNS prophylaxis for elderly patients with DLBCL
Andrew M Evens, DO, MSc
Professor of Medicine
Chief, Division of Hematology/Oncology
Tufts University School of Medicine
Director, Lymphoma Program Leader, Clinical Sciences Program
Tufts Cancer Center
Boston, Massachusetts
Christopher Flowers, MD, MS
Associate Professor of Hematology
and Medical Oncology
Emory School of Medicine
Winship Cancer Institute
Atlanta, Georgia
Jonathan W Friedberg, MD, MMSc
Samuel Durand Professor of Medicine
Director, Wilmot Cancer Center University of Rochester
Rochester, New York
Julie M Vose, MD, MBA
Neumann M and
Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Professor of Medicine
Nebraska Medical Center
Omaha, Nebraska
Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia School of Medicine
Charlottesville, Virginia
Neil Love, MD
Research To Practice
Miami, Florida